Xencor (XNCR) Profit After Tax (2013 - 2026)
Xencor (XNCR) posted quarterly Profit After Tax of -$130.5 million for Q1 2026, down 169.46% year-over-year from $187.8 million in Q1 2025, and down 1439.59% quarter-over-quarter from -$8.5 million in Q4 2025.
Analysis
Xencor (XNCR) Profit After Tax (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Profit After Tax for 14 consecutive years, with -$130.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 169.46% year-over-year to -$130.5 million; the TTM figure through Mar 2026 stood at -$175.8 million (up 16.04% YoY), while the FY2025 annual figure was -$91.9 million, up 60.81% from the prior year.
- Profit After Tax slipped to -$130.5 million in Q1 2026 per XNCR's latest filing, from -$8.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $18.0 million in Q1 2022 and bottomed at -$130.5 million in Q1 2026.
- Historically, Profit After Tax has averaged -$38.1 million across 5 years, with a median of -$33.7 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax jumped 829.83% — and 2023, when it slumped 437.89%.
- Xencor's Profit After Tax stood at -$12.0 million in 2022, then tumbled by 50.03% to -$18.1 million in 2023, then sank by 147.64% to -$44.7 million in 2024, then surged by 81.06% to -$8.5 million in 2025, then sank by 1439.59% to -$130.5 million in 2026.
- Business Quant data shows XNCR's Profit After Tax at -$130.5 million in Q1 2026, -$8.5 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Xencor | 2.02 Bn | 1.64 Bn | - | -22.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.63 Mn |
| Mar 31, 2026 | -128.92 Mn |
| Dec 31, 2025 | -6.65 Mn |
| Sep 30, 2025 | -6.03 Mn |
| Jun 30, 2025 | -30.92 Mn |
| Mar 31, 2025 | -48.63 Mn |
| Dec 31, 2024 | -48.15 Mn |
| Sep 30, 2024 | -47.44 Mn |
| Jun 30, 2024 | -68.78 Mn |
| Mar 31, 2024 | -74.12 Mn |
| Dec 31, 2023 | -26.31 Mn |
| Sep 30, 2023 | -24.27 Mn |
| Jun 30, 2023 | -20.19 Mn |
| Mar 31, 2023 | -57.44 Mn |
| Dec 31, 2022 | -9.12 Mn |
| Sep 30, 2022 | -33.69 Mn |
| Jun 30, 2022 | -35.80 Mn |
| Mar 31, 2022 | 17.98 Mn |
| Dec 31, 2021 | 73.06 Mn |
| Sep 30, 2021 | -40.25 Mn |